MARCH | 2026
CASE STUDY RAPID SEPSIS DETECTION WITH ddPCR
Meridian's Chemistry Elevates ddPCR-Based Sepsis Testing
DRIVING DIAGNOSTIC INNOVATION
Lyo-Ready 1-Step RT-qPCR Mix (MDX024) , which exhibited high amplification efficiency, enhanced specificity, strong inhibitor tolerance and excellent lyophilization compatibility. These features support the use of MDX024 as a suitable reagent for ddPCR- based sepsis assay development. Its versatile formulation underscores Meridian’s commitment to advancing molecular diagnostics, providing high-performing reagents that deliver consistency, flexibility and confidence across diverse platforms and clinical applications. 4. Gaieski, D. F., et al . (2010). Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department*. Critical Care Medicine, 38 (4), 1045–1053. https://doi.org/10.1097/ccm.0b013e3181cc4824 5. Hu, B., et al. (2021). A comparison of blood pathogen detection among droplet digital PCR, metagenomic Next-Generation sequencing, and blood culture in critically ill patients with suspected bloodstream infections. Frontiers in Microbiology, 12. https://doi.org/10.3389/fmicb.2021.641202 6. Wu, Z., et al. (2024). Sensitive and rapid identification of pathogens by droplet digital PCR in a cohort of septic patients: a prospective diagnostic study. Infectious Diseases, 56 (10), 830–841. https:// doi.org/10.1080/23744235.2024.2354312
Sepsis remains a leading cause of mortality among critically ill patients and early, accurate pathogen detection is essential for effective clinical intervention. Traditional blood culture methods are time-consuming and often lack sensitivity, highlighting the need for faster and more reliable diagnostic approaches. This case study evaluated the clinical utility of droplet digital PCR (ddPCR), demonstrating earlier pathogen detection compared with conventional blood culture workflows in patients with suspected sepsis. The study also highlighted the exceptional performance of Meridian’s REFERENCES 1. Fleischmann, C., et al. (2015). Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. American Journal of Respiratory and Critical Care Medicine , 193 (3), 259–272. https://doi.org/10.1164/rccm.201504- 0781oc 2. Kumar, A., et al. (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*. Critical Care Medicine , 34 (6), 1589–1596. https://doi.org/10.1097/01.ccm.0000217961.75225.e9 3. Kumar, A. (2014). Antimicrobial delay and outcome in severe sepsis. Critical Care Medicine, 42 (12), e802. https://doi.org/10.1097/ ccm.0000000000000620
TO LEARN MORE | Discover how Meridian's molecular solutions can help you optimize your sepsis workflows. From high-performance PCR chemistries to custom formulations and scalable manufacturing, we provide the tools and expertise to accelerate your assay development. VISIT | www.meridianbioscience.com/lifescience
ABOUT MERIDIAN
Pilot Gene is an innovative high-tech company specializing in molecular diagnostics, molecular biology, and genetics. Headquartered in Hangzhou, China, it is committed to becoming a leading global provider of molecular diagnostics and life science solutions. With a strong focus on droplet digital PCR (ddPCR) technology, Pilot Gene has developed high-throughput, fully automated digital PCR systems widely used in clinical diagnostics, life sciences, and public health. Backed by over 10 years of experience, the company continues to strengthen its R&D capabilities and expand its global presence through continuous innovation. ABOUT PILOT GENE
Meridian is a global provider of innovative diagnostic solutions and critical raw materials for molecular and immunoassay development. We design, manufacture and deliver components that enable fast, accurate and reliable diagnostics—from early research through commercial testing. As part of our molecular focus, we offer a comprehensive portfolio of: • Enzymes for isothermal, qPCR and NGS sample prep Our solutions, engineered for workflow efficiency, sensitivity and reproducibility, enable applications from infectious disease detection to precision oncology. Backed by deep technical expertise and global manufacturing capabilities, we deliver consistent quality, rapid turnaround and scalable supply—empowering diagnostic innovators to accelerate development and bring products to market with confidence. • Optimized master mixes for LAMP and qPCR • Nucleotides and other supporting reagents
meridianbioscience.com/lifescience EMAIL info@meridianlifescience.com ORDERS orders@meridianlifescience.com
5171 Wilfong Road Memphis, TN, USA 38134
PHONE +1 901-382-8716 FAX +1 901-333-8223
Powered by FlippingBook